Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Fred Lampropoulos, the President and CEO of Merit Medical Systems Inc. (NASDAQ:MMSI), has sold a significant portion of the company’s stock, according to a recent SEC filing. On March 5, Lampropoulos sold a total of 34,319 shares of common stock in multiple transactions. The sales were executed at prices ranging from $103.75 to $104.05 per share, totaling approximately $3.56 million. The timing is notable as the stock trades near its 52-week high of $111.45, with an impressive 40% return over the past year. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
Following these transactions, Fred Lampropoulos holds 1,086,028 shares directly. Additionally, shares are held indirectly through a 401(k) plan and by his spouse as custodian for a child. The sales come as part of routine financial management and investment diversification by the executive. The $6 billion market cap company maintains excellent financial health, earning a "GREAT" rating from InvestingPro, with strong liquidity and moderate debt levels.
Merit Medical Systems is a Utah-based company specializing in surgical and medical instruments and apparatus. The company’s stock performance and executive transactions are closely monitored by investors, given the impact such sales can have on market perception. With a P/E ratio of 49.4, the stock trades at premium multiples. Discover more detailed valuation metrics and 12+ additional ProTips with InvestingPro.
In other recent news, Merit Medical Systems reported fourth-quarter earnings that exceeded expectations, with earnings per share (EPS) of $0.93, surpassing the projected $0.82. The company’s revenue for the quarter was $355.2 million, also exceeding the anticipated $346.76 million. Analysts from Oppenheimer, Needham, and Raymond (NSE:RYMD) James have all adjusted their price targets for Merit Medical (TASE:BLWV) to $116, reflecting varied outlooks on the company’s performance and future potential. Despite the EPS guidance for 2025 being slightly below consensus, Raymond James expressed confidence in the company’s ability to exceed its forecasts, citing strong historical growth and operational achievements. Merit Medical’s acquisitions, including Cook Medical and EndoGastric Solutions, have been performing well, contributing to the company’s robust free cash flow, which increased by 67% to $185 million in 2024. The company has provided a sales guidance for 2025, anticipating 5.5-6.5% organic growth, and has set expectations for the WRAPSODY system sales to reach $7-9 million. Analysts at Needham believe these figures might be conservative, given the company’s strategic execution and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.